New Alzheimer's treatment clears FDA hurdle

A new drug for Alzheimer's Disease has cleared another hurdle to getting approval from the FDA. The agency's advisory panel unanimously recommended full approval of a new antibody drug shown to slow down the disease. The treatment from Eli Lilly called Donanemab, attacks a type of sticky plaque in the brain that leads to memory loss. If the FDA approves the drug this year, it will become the second on the market to slow down the progression of cognitive decline.